Patents by Inventor Brian Toki

Brian Toki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11319526
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: May 3, 2022
    Assignee: Seagen Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Patent number: 10443035
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 15, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20190276796
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: May 16, 2019
    Publication date: September 12, 2019
    Inventors: Stephen C. ALLEY, Scott C. JEFFREY, Django SUSSMAN, Dennis R. BENJAMIN, Brian TOKI, Patrick J. BURKE
  • Publication number: 20180155677
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: October 10, 2017
    Publication date: June 7, 2018
    Inventors: Stephen C. ALLEY, Scott C. Jeffrey, Django SUSSMAN, Dennis R. BENJAMIN, Brian TOKI, Patrick J. BURKE
  • Patent number: 9816069
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 14, 2017
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20150337259
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: February 26, 2015
    Publication date: November 26, 2015
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Patent number: 8993326
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: March 31, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20140031536
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: October 1, 2013
    Publication date: January 30, 2014
    Applicant: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Patent number: 8574907
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: November 5, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20120183997
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: February 24, 2012
    Publication date: July 19, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: STEPHEN C. ALLEY, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Patent number: 8163551
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: April 24, 2012
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20090317869
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: May 1, 2009
    Publication date: December 24, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20070258987
    Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
    Type: Application
    Filed: May 28, 2004
    Publication date: November 8, 2007
    Inventors: Joseph Francisco, Grant Risdon, Alan Wahl, Clay Siegall, Peter Senter, Doronina Svetlana, Brian Toki
  • Publication number: 20070160617
    Abstract: This invention relates generally to antibody-drug conjugates (ADCs). In particular, the invention relates to ADCs which comprise an antibody or antigen-binding fragment thereof which binds to prostate-specific membrane antigen (PSMA) and is conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine. The antibody-drug conjugate has a PC-3™ cell to C4-2 or LNCaP™ cell selectivity of at least 250. The invention also relates, in part, to compositions of and methods of using the ADCs. The methods provided include, for example, methods for treating a PSMA-mediated disease.
    Type: Application
    Filed: June 20, 2006
    Publication date: July 12, 2007
    Applicant: PSMA Development Company, LLC
    Inventors: Dangshe Ma, Paul Maddon, William Olson, Svetlana Doronina, Brian Toki, Peter Senter
  • Publication number: 20060229253
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieties, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Application
    Filed: June 12, 2006
    Publication date: October 12, 2006
    Inventors: Svetlana Doronina, Peter Senter, Brian Toki
  • Publication number: 20060074008
    Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: July 31, 2003
    Publication date: April 6, 2006
    Inventors: Peter Senter, Svetlana Doronina, Brian Toki
  • Publication number: 20050238649
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: November 5, 2004
    Publication date: October 27, 2005
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana Doronina, Peter Senter, Brian Toki, Allen Ebens, Toni Kline, Paul Polakis, Mark Sliwkowski, Susan Spencer
  • Publication number: 20050214310
    Abstract: Shown and described are the synthesis of more potent forms of C-Mel, a prodrug used in Antibody-Directed Enzyme Prodrug Therapy, that releases the clinically used anticancer alkylating agent melphalan extracellularly. Shown and described are the synthesis of a variety of melphalan analogues with the intention to promote facile intracellular drug access. Esters, amides, and peptides of melphalan are shown. Cephalosporin prodrugs of the most interesting melphalan derivatives were synthesized and evaluated for potency, toxicity, therapeutic window, plasma stability, and solubility.
    Type: Application
    Filed: January 24, 2005
    Publication date: September 29, 2005
    Applicant: Seattle Genetics, Inc.
    Inventors: Brian Toki, Peter Senter
  • Patent number: 6943194
    Abstract: A newly discovered antineoplastic compound denominated “phenstatin” is herein described as are synthetic methods for producing phenstatin and the active prodrug thereof. Phenstatin was converted to the sodium phosphate prodrug (3d) by a dibenzylphosphite phosphorylation and subsequent hydrogenolysis sequence 3b?3c?3d. Phenstatin (3b) was found to be a potent inhibitor of tubulin polymerization and the binding of colchicine to tubulin comparable to combretastatin A-4 (1b).
    Type: Grant
    Filed: January 9, 1999
    Date of Patent: September 13, 2005
    Assignee: Arizona Board of Regents, acting for and on behalf of Arizona State University
    Inventors: George R. Pettit, Brian Toki
  • Publication number: 20050123536
    Abstract: The present invention relates to methods for the treatment of immunological disorders other than cancer, comprising administering proteins characterized by their ability to bind to CD30 and exert a cytostatic or cytotoxic effect on an activated lymphocyte. Such proteins include monoclonal antibodies AC10 and IleFi1. AC10 and HeFi-1 derivatives, and antibodies that compete with AC10 and HeFi-1 for binding to CD30. Other such proteins include multivalent anti-CD30 antibodies and anti-CD30 antibodies conjugated to cytotoxic agents. Treatment modalities with antibodies of the invention are also provided.
    Type: Application
    Filed: November 20, 2002
    Publication date: June 9, 2005
    Inventors: Che-Leung Law, Kerry Klussman, Alan Wahl, Peter Senter, Svetlana Doronina, Brian Toki